Artem Pilunov

Dr. Artem Pilunov

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ASAlina S. Shomuradova
Alina S. Shomuradova
Murad VagidaMurad Vagida
Murad Vagida
SSSavely A. Sheetikov
Savely A. Sheetikov
KZKsenia V. Zornikova
Ksenia V. Zornikova
DKDmitry Kiryukhin
Dmitry Kiryukhin
GEGrigory A. Efimov
Grigory A. Efimov
Summary: Understanding the hallmarks of the adaptive immune response to SARS-CoV-2 is critical for fighting the COVID-19 pandemic. We assessed the antibody and T-cell reactivity in COVID-19 convalescent patients and healthy donors sampled both prior to and during the pandemic. The numbers of SARS-CoV-2-specific T cells were increased in healthy donors examined during COVID-19. Combined with the absence of symptoms and humoral response across that group, this finding suggests that some individuals might be protected by T-cell cross-reactivity. In convalescent patients we observed public and diverse T-cell response to SARS-CoV-2 epitopes, revealing T-cell receptor motifs with germline-encoded features. Bulk CD4+ and CD8+ T-cell responses to Spike glycoprotein were mediated by groups of homologous T-cell receptors, some of them shared across multiple donors. Overall, our results demonstrate that T-cell response to SARS-CoV-2, including the identified set of specific T-cell receptors, can serve as a useful biomarker for surveying viral exposure and immunity.

3 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
APArtem Pilunov
Artem Pilunov
DRDmitrii S. Romaniuk
Dmitrii S. Romaniuk
ASAnton Shmelev
Anton Shmelev
SSSavely Sheetikov
Savely Sheetikov
AGAnna Gabashvili
Anna Gabashvili
GEGrigory A. Efimov
Grigory A. Efimov
A significant share of allogeneic hematopoietic stem cell transplantations (allo-HSCT) results in the relapse of malignant disease. The T cell immune response to minor histocompatibility antigens (MiHAs) promotes a favorable graft-versus-leukemia response. The immunogenic MiHA HA-1 is a promising target for leukemia immunotherapy, as it is predominantly expressed in hematopoietic tissues and presented by the common HLA A*02:01 allele. Adoptive transfer of HA-1-specific modified CD8+ T cells could complement allo-HSCT from HA-1- donors to HA-1+ recipients. Using bioinformatic analysis and a reporter T cell line, we discovered 13 T cell receptors (TCRs) specific for HA-1. Their affinities were measured by the response of the TCR-transduced reporter cell lines to HA-1+ cells. The studied TCRs showed no cross-reactivity to the panel of donor peripheral mononuclear blood cells with 28 common HLA alleles. CD8+ T cells after endogenous TCR knock out and introduction of transgenic HA-1-specific TCR were able to lyse hematopoietic cells from HA-1+ patients with acute myeloid, T-, and B-cell lymphocytic leukemia (n = 15). No cytotoxic effect was observed on cells from HA-1- or HLA-A*02-negative donors (n = 10). The results support the use of HA-1 as a target for post-transplant T cell therapy.

1 May 2019 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
APArtem Pilunov
Artem Pilunov
AKA. A. Kuchmiy
A. A. Kuchmiy
SSS. A. Sheetikov
S. A. Sheetikov
SFS. Y. Filkin
S. Y. Filkin
DRD. S. Romaniuk
D. S. Romaniuk
GEG. A. Efimov
G. A. Efimov
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for hematopoietic malignancies. The graft-derived donor lymphocytes are capable of eliminating the...

13 September 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
DRD. S. Romanyuk
D. S. Romanyuk
APArtem Pilunov
Artem Pilunov
GEG. A. Efimov
G. A. Efimov
ABApollinariya Bogolyubova
Apollinariya Bogolyubova
EPE. N. Parovichnikova
E. N. Parovichnikova
Minor histocompatibility antigens (MiHAs) are polymorphic peptides on the cell surface derived from self-proteins that are capable to induce an immune response during allogeneic hematopoietic stem cells transplantation. Their presentation occurs in the context of the certain major histocompatibility complex (HLA – human leucocyte antigen) alleles. One of the most common HLA alleles is HLA-A*02:01. Accordingly, for a significant number of donors and recipients pairs, it is possible to use the MiHAs presented in the HLA-A*02:01 as a target for relapsed leukemia therapy. This review discusses the main known MiHAs presented in the context of HLA-A*02:01, their characteristics and approaches used for identification. The described approaches may be used to search for new MiHAs for immunotherapy.

25 October 2021 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
APArtem Pilunov
Artem Pilunov
DRD. S. Romaniuk
D. S. Romaniuk
GEG. A. Efimov
G. A. Efimov
VSV. G. Savchenko
V. G. Savchenko
Introduction. Minor histocompatibility antigens (MiHAs) — polymorphic peptides presented in HLA molecules that are products of genes containing nonsynonymous single nucleotide polymorphisms. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the immune response directed to MiHA can result both in graft-versus-host and graft-versus-tumor responses.Some MiHAs are promising and safe targets for T-cell immunotherapy of leukemia relapse after allo-HSCT.Aim — to analyze the literature describing the immune response to various MiHAs, as well as clinical trials using MiHAs as targets of immunotherapy.Main findings. MiHAs represent promising targets for the prevention or therapy of leukemia relapse after allo-HSCT due to their advantages over tumor-associated antigens and neoantigens. To be suitable for immunotherapy, MiHA must satisfy several parameters: 1) be presented by a common HLA allele, 2) have an optimal frequency of polymorphism-encoding allele, 3) be encoded by a gene that is predominantly expressed in hematopoietic tissue. This drastically limits the number of applicable targets and makes the discovery of new MiHAs highly relevant.

1 January 2019 in Molekulârnaâ biologiâ
Verified
Journal Article
Closed access
APArtem Pilunov
Artem Pilunov
АКА. А. Кучмий
А. А. Кучмий
СШС. А. Шитиков
С. А. Шитиков
СФС. Ю. Филькин
С. Ю. Филькин
ДРД. С. Романюк
Д. С. Романюк
ГЕГ. А. Ефимов
Г. А. Ефимов
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for hematopoietic malignancies. The graft-derived donor lymphocytes are capable of eliminating the residual recipient malignant cells in the course of allogeneic immune response, thus decreasing the chances of a relapse of the disease. Foreign peptides of the recipient presented by the MHC molecules are able to elicit the immune response immunologically. These polymorphic peptides are known as minor histocompatibility antigens (MiHAs). MiHAs occur due to the nonsynonymous single nucleotide polymorphisms in human genome. Transfusion of T cells specific to MiHAs presented predominantly in the cells of hematopoietic origin will allow the targeted elimination of residual malignant clones avoiding undesirable damage to healthy tissues. To induce the immune response, the donor must be homozygous by the MiHA allele and the recipient must either be homozygous or heterozygous by the alternative MiHA allele. The therapeutic mismatch occurs in 25% of cases under the optimal frequency of allelic variants. Minor antigen ACC-1Y originates from polymorphism in the BCL-2A1 gene; its immunogenic mismatch occurrence approaches the theoretical maximum. In addition, BCL2A1 is overexpressed in cells of various lymphomas. ACC-1Y is presented on allele HLA-A*24:02, which is relatively frequent in the Russian population. Combination of these factors makes the minor antigen ACC-1Y a promising target for immunotherapy. Transfusion of donor CD8^(+) lymphocytes modified with transgenic MiHA-specific TCR is one of the promising methods of posttransplant leukemia therapy and relapse prophylaxis. We obtained a sequence of high-affinity ACC-1Y-specific TCR after the antigen-specific expansion of T cells derived from a healthy ACC-IY^(-/-) donor. We cloned this sequence into the lentiviral vector and obtained the assembled viral particles. Further, we transduced the CD8^(+) lymphocyte culture and demonstrated its antigen-specific cytotoxic activity. It is suggested that CD8^(+) lymphocytes modified by the described method could be potentially transferred to recipients as a therapy against relapse after allo-HSCT.